ST Germain D J Co. Inc. Buys 2,400 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

ST Germain D J Co. Inc. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 24.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,356 shares of the medical research company's stock after buying an additional 2,400 shares during the period. ST Germain D J Co. Inc.'s holdings in Thermo Fisher Scientific were worth $6,148,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of TMO. Vanguard Group Inc. lifted its holdings in Thermo Fisher Scientific by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock valued at $17,297,426,000 after acquiring an additional 196,864 shares during the period. Capital World Investors lifted its holdings in Thermo Fisher Scientific by 1.1% in the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock valued at $4,905,812,000 after acquiring an additional 104,343 shares during the period. Geode Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after acquiring an additional 197,442 shares during the period. Norges Bank bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $3,149,754,000. Finally, Northern Trust Corp lifted its holdings in Thermo Fisher Scientific by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after acquiring an additional 455,004 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $3.75 during mid-day trading on Wednesday, hitting $403.68. 2,280,607 shares of the stock were exchanged, compared to its average volume of 1,892,305. The firm has a 50-day moving average of $426.27 and a two-hundred day moving average of $498.03. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a market cap of $152.39 billion, a PE ratio of 24.42, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business's revenue was up .2% on a year-over-year basis. During the same period last year, the company posted $5.11 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Argus lowered their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Scotiabank decreased their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research note on Friday, April 25th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. UBS Group decreased their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Finally, Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.